Healthcare Technologies 2012
With the increasing importance of biomarkers and diagnostics in diseases detection, patient management and clinical trials, the demand for technologies that can selectively and reproducibly quantify the detection of such biomarkers continues to grow. A number of commentators and industry executives are starring to suggest that in maybe a s little as five years, the regulators such as FDA and EMA will require the companion diagnostic to be available before a new drug will be approved. This will mean continued integration of the appropriate disciplines such as diagnostic validation, bioinformatics, medicinal chemistry and pharmacology will be required to develop new therapeutic entities. The wider context of such inter-dependent approaches has potentially far reaching implications
The latest in our Leadership Series event will see presentations that will illustrate ‘state of the art’ when it comes to the technologies, economics and regulatory hurdles in personalised medicine, stimulating debate on how best the sector, as well as the individual companies within it, can capture the best healthcare and commercial returns from the exponential advances in the capability to target the right drug to the right patient at the right time.
Summary of Event Programme:
09.30 - Registration, Coffee and Networking
10.00 - Welcome and Introduction
10.05 - Plenary Session
11.30 - Stream A: Personalised Medicine
Stream B: Biosensors
14.00 - Stream A: Patient Stratification Technologies
Stream B: Smart Materials in Medical Devices
16.00 - Stream A: Point-of-Care Diagnostics
Stream B: Funding Medical Technology Development
18.30 - Close